METHOD FOR PREDICTION OF COLD AIRWAY HYPERREACTIVITY CORRECTION EFFICIENCY IN BRONCHIAL ASTHMA PATIENTS WITH APPLICATION OF EXTRA-FINE AEROSOL FOR INHALATIONS OF BECLOMETHASONE DIPROPIONATE/FORMOTEROL FUMARATE
Nakhamchen Leonid Girshevich (RU),Нахамчен Леонид Гиршевич (RU),Afanaseva Evgeniya Yurevna (RU),Афанасьева Евгения Юрьевна (RU),Prikhodko Anna Grigorevna (RU),Приходько Анна Григорьевна (RU),Perelman
申请号：
RU2019129208
公开号：
RU0002721415C1
申请日:
2019.09.16
申请国别(地区):
RU
年份:
2020
代理人:
摘要：
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to pulmonology, and can be used for prediction of efficiency of cold airway hyperreactivity correction in patients with mild and moderate bronchial asthma when using extramelic aerosol for inhalations of beclomethasone dipropionate/formoterol fumarate. For this purpose, patients undergo a questionnaire with score of 7 clinical symptoms (symptom severity is assessed in points 1 to 7) observed in winter period in contact with cold: 1 - shortness of breath； 2 - intensified dyspnoea at usual daily load on the street； 3 shows coughing gain or appearance； 4 - occurrence of pain, discomfort, chest stiffness (behind the sternum)； 5 - occurrence of nasal congestion； 6 shows mucous discharge from nose； 7 is an increase in the number of doses of the used broncholytic； total score is calculated (B). That is followed by evaluating the severity of respiratory reaction in response to inhalation of 400 mcg of β2-adrenomimetic salbutamol by changing the volume of forced exhalation in 1 second (in % of the initial value) after performing the test with broncholytic (ΔFEV1B). Forecast is carried out by comparing the value D calculated using the equation D = 2.361 × B + 0.397 × ΔFEV1B, with its boundary value (+55.88). If D is less than the boundary value, efficiency of correction of cold airway hyperreactivity is predicted, if D is equal to or exceeds the limit value, correction inefficiency is predicted.EFFECT: method enables optimizing the therapeutic approach to the patients with mild and moderate bronchial asthma with cold airway hyperreactivity with reducing the length of selecting the optimal method of treatment.1 cl, 3 tbl, 2 exИзобретение относится к медицине, а именно к пульмонологии, и может быть использовано для прогнозирования эффективности коррекции холодовой гиперреактивности дыхательных путей у больных легкой и среднетяжелой бронхиальной астмой при применении экстрамелкодисперсного аэрозоля для ингаляций бек
